National Pharmaceuticals Corp
PINK SHEETS : NFRM

March 16, 2011 09:01 ET

National Pharmaceuticals Corp. Appoints Chief Scientific Advisor

MIAMI, FLORIDA--(Marketwire - March 16, 2011) - National Pharmaceuticals Corp. (PINK SHEETS:NFRM) or the "Company" announced today that it has appointed Dr. Gary Yalloway as its Chief Scientific Advisor.

Dr. Yalloway is a well known leading researcher on cytokines and growth factors. He has designed the production of GLB333 through recombinant technologies at Globe Laboratories where he currently is the Chief Operating Officer and Head of all Technologies. He brings to NFRM over 14 years of multidisciplinary research experience and skills in protein engineering and the structural functional relationships of proteins of medical and industrial interest.

Dr. Yalloway earned his Ph.D. from University College, Dublin, Ireland and was a post doctoral fellow at the Institute for Biophysical Chemistry, Frankfurt, Germany and the University of British Columbia, Vancouver, Canada. Dr Yalloway was also a postdoctoral research associate at Simon Fraser University where he was lab manager and a team leader responsible for the project management of junior scientists. He served as senior research officer at Chemokine Therapeutics.

"Dr. Yalloway has outstanding skills and vast experience in biopharmaceutical drugs development.", said Elaine Affleck, President of National Pharmaceuticals Corp. "We are pleased to have Dr. Yalloway lead our scientific team and supervise the development of GLB333", Added Ms. Affleck.

About National Pharmaceuticals Corp.

National Pharmaceuticals Corp. is a Pharmaceutical Research and Development Corporation focused on leading edge technologies for treatment of human diseases. The company has embarked into the business of licensing mid stage development drugs for further development and marketing worldwide.

Forward-looking Statements - Important Information about Forward-Looking Statements in this press release is within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above.

Contact Information

  • National Pharmaceuticals Corporation
    Elaine Affleck
    (954) 903-1967